Monosialotetrahexosy lganglioside for vascular cognitive impairment: an efficacy observation
10.3760/cma.j.issn.1673-4165.2011.05.007
- VernacularTitle:单唾液酸四己糖神经节苷脂治疗血管性认知障碍的疗效观察
- Author:
Zhonglin LIU
;
Limin WANG
;
Jun LIU
;
Songhua XIAO
;
Yamei TAN
- Publication Type:Journal Article
- Keywords:
Cognition disorders;
Cerebrovascular disorders;
Gangliosides
- From:
International Journal of Cerebrovascular Diseases
2011;19(5):386-388
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of monosialotetrahexosy lganglioside (GM1) in the treatment of vascular cognitive impairment (VCI). Methods Sixty patients with VCI were randomly divided into either a treatment group or a control group. The patients in the control group received conventional treatment and those in the treatment control group were treated with conventional treatment plus continuous intravenous infusion of GM1 (80 mg/d) for 2 weeks. The efficacy was evaluated by the Montreal Cognitive Assessment (MoCA) before and after the treatment, and the safety of the treatment was observed. Results After 2 weeks of treatment, the MoCA scores were significantly higher than those before treatment in both groups (all P ＜ 0. 05). The MoCA scores of the treatment group were significantly higher than those of the control group (20. 82 ± 1. 96 vs. 19. 61 ±2. 02, t =2. 315, P =0. 023). No obvious adverse reactions were found. Conclusions The efficacy of GM1 is positive in the treatment of vascular cognitive impairment, and there is no obvious adverse reactions. It is worthy of using widely in clinical practice.
